These results indicate that the anti‐HER‐2 scFv prepared by the prokaryotic expression system specifically bound to the breast cancer cell surface antigen, HER‐2, and had equivalent level of targeting as monoclonal antibodies. This evidence concerns the gene ERBB2 and breast cancer.